Investigating non-invasive brain stimulation for drug-resistant epilepsy
Official title: Evaluating Modulation Effects of Temporal Interference Using SEEG
Run by Xuanwu Hospital, Beijing · NCT06663969 · Data updated 2026-11-12
This study is testing a new non-invasive brain stimulation method to see if it can help people aged 14-60 with epilepsy that doesn't respond to medication.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 14 Years to 65 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | November 4, 2024 |
| Main results expected | September 2025 |
| Study ends | October 2025 |
| Registry record updated | February 5, 2025 |
| Trial ID | NCT06663969 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 14-60 with a clinical diagnosis of drug-resistant epilepsy who have undergone implantation of stereotactic electrodes.
✕Probably not a fit
Patients with severe systemic diseases or complications at the electrode site may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective study explores the effects of temporal interference (TI) on deep brain stimulation in patients aged 14-60 with drug-resistant epilepsy. By utilizing stereoelectroencephalography (SEEG), the study aims to analyze the electrophysiological mechanisms of TI, which generates focused stimulation in targeted brain areas without invasive procedures. Clinical, imaging, and electrophysiological data will be collected and analyzed to enhance understanding of TI's impact on brain function and its potential as a treatment alternative.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive treatment option for patients with drug-resistant epilepsy.
How similar studies have gone: While temporal interference is a novel approach, similar studies in non-invasive brain stimulation have shown promising results, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of drug-resistant epilepsy; * No severe systemic diseases; * Implantation of stereotactic electrodes; * Agreement to participate in this study and signs the informed consent form. Exclusion Criteria: * Hematoma at the scalp electrode site or fluid accumulation under the electrode after intracranial electrode placement.
Where it's running
-
Xuanwu Hospital,Capital Medical University
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Liankun Ren, MD — Xuanwu Hospital, Beijing
- Study coordinator: Liankun Ren, MD
- Email: renlk2022@outlook.com
- Phone: +86 13681576621
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Modified ketogenic diet for adults with drug-resistant epilepsy
This study tests whether a modified ketogenic diet can help adults with drug-resistant epilepsy see fewer seizures and feel better overall.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
See if deep brain stimulation for Parkinson's changes thinking and movement and affects fall risk
This pilot study tests whether deep brain stimulation in people with Parkinson’s changes thinking or movement and whether those changes relate to how often they fall.
-
Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy
This study tests whether low intensity focused ultrasound can help reduce seizures in adults with drug‑resistant epilepsy.
-
iVEAcare Neuromodulation System for drug‑resistant epilepsy: a feasibility look
This study tests whether the iVEAcare neuromodulation system is safe and can help reduce seizures and improve quality of life in people with drug‑resistant epilepsy.
-
Real-world use of the OneRF Ablation System for epilepsy
This registry collects real-world outcomes and device performance from patients with drug-resistant epilepsy who are treated with SEEG-guided RF ablation using the OneRF system.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.